Purpose: Ameloblastoma of the human jaw is an uncommon but clinically significant odontogenic epithelial neoplasm. The aim was to analyze the clinicopathologic characteristics of ameloblastoma in a Malaysian population. Materials and Methods: This is a retrospective study (1993 through 2008) of consecutive ameloblastoma cases accessioned in 2 main oral pathology diagnostic centers: the Unit of Stomatology, Institute for Medical Research and the Department of Oral Pathology, Oral Medicine, and Periodontology, Faculty of Dentistry, University of Malaya, Kuala Lumpur, Malaysia. Data on patient demographics, tumor location, symptomology, duration, radiographic appearance, preoperative diagnosis, clinicopathologic subtypes, treatment, and recurrence were analyzed. Results: Three hundred forty cases of ameloblastoma were reviewed. These were from 197 male patients (57.9%) and 143 female patients (42.1%), with a male-to-female ratio of 1.4:1. A wide age range (7 to 85 years), mean onset age of 30.3 ± 16.3 years, and peak incidence in the second decade of life were recorded. Most were mandibular tumors (n = 311/340, 91.5%). These consisted of 95 (28%) unicystic ameloblastomas, 221 (65%) solid/multicystic meloblastomas, 22 (6.4%) desmoplastic ameloblastoma, and 2 (0.6%) peripheral ameloblastomas. Unicystic ameloblastoma (41.1%) and solid/multicystic ameloblastoma (52.0%) mostly affected Malays patients, whereas desmoplastic ameloblastoma (59.1%) was prevalent in Chinese patients. Unicystic ameloblastoma (56.8%) and solid/multicystic ameloblastoma (47.1%) occurred predominantly in the body and posterior mandible, whereas desmoplastic ameloblastoma (36.4%) preferentially involved the anterior jaw segment. Most tumors presented as multilocular radiolucencies (36.8%). Enucleation (n = 42/92, 45.7%) was the treatment of choice. About 18 cases (13.3%) presented with recurrence. Conclusions: Because ameloblastoma subsets differ in their biologic behavior, the present data are significant as baseline references for clinicians and pathologists.

The presence of lymph node (LN) metastasis significantly affects the survival of patients with oral squamous cell carcinoma (OSCC). Successful detection and removal of positive LNs are crucial in the treatment of this disease. Current evaluation methods still have their limitations in detecting the presence of tumor cells in the LNs, where up to a third of clinically diagnosed metastasis-negative (N0) patients actually have metastasis-positive LNs in the neck. We developed a molecular signature in the primary tumor that could predict LN metastasis in OSCC. A total of 211 cores from 55 individuals were included in the study. Eleven proteins were evaluated using immunohistochemical analysis in a tissue microarray. Of the 11 biomarkers evaluated using receiver operating curve analysis, epidermal growth factor receptor (EGFR), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (HER-2/neu), laminin, gamma 2 (LAMC2), and ras homolog family member C (RHOC) were found to be significantly associated with the presence of LN metastasis. Unsupervised hierarchical clustering–demonstrated expression patterns of these 4 proteins could be used to differentiate specimens that have positive LN metastasis from those that are negative for LN metastasis. Collectively, EGFR, HER-2/neu, LAMC2, and RHOC have a specificity of 87.5% and a sensitivity of 70%, with a prognostic accuracy of 83.4% for LN metastasis. We also demonstrated that the LN signature could independently predict disease-specific survival (P = .036). The 4-protein LN signature validated in an independent set of samples strongly suggests that it could reliably distinguish patients with LN metastasis from those who were metastasis-free and therefore could be a prognostic tool for the management of patients with OSCC.